Results 191 to 200 of about 513,632 (295)

Treatment of Atopic Dermatitis with Upadacitinib in a Patient During Hepatitis C Activity Period. [PDF]

J Asthma Allergy
Huang J, Wang M, Gao XH, Zhang L.
europepmc   +1 more source

Interferon treatment for chronic hepatitis C virus infection in uremic patients

, 1994
Paul-Albert Koenig, W. Vogel, Florian Umlauft, Katharina Weyrer, Rupert Prommegger, Karl Lhotta, Ulrich Neyer, Hans–Krister Stummvoll, K Gruenewald   +8 more
openalex   +1 more source

Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein. [PDF]

, 1991
Barbara Hosein, Fang Chen, Mark A. Popovsky, J Ye, M Zhang, C Y Wang   +5 more
openalex   +1 more source

Harnessing Viral Proteases for Cellular and Molecular Engineering

Chemistry–Methods, EarlyView.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui, Tien‐Hung Lan, Yubin Zhou   +2 more
wiley   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez, Zhao Yang, William R Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +5 more
wiley   +1 more source

Direct-Acting Antivirals and Risk of Hepatitis C Extrahepatic Manifestations.

JAMA Netw Open
Jeong D, Wong S, Karim ME, Manges AR, Makuza JD, Velásquez García HA, Adu PA, Binka M, Yu A, Bartlett SR, Krajden M, Janjua NZ.   +11 more
europepmc   +1 more source

Psoriasiform Dermatitis: A Peculiar Presentation in the Setting of Staphylococcus aureus Bacteremia and Hepatitis C. [PDF]

Cureus
Shahid NUA, Saleem N, Juveria S, Zubair M.   +3 more
europepmc   +1 more source

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

Hepatitis C Testing Protocols Across Massachusetts Jails, 2022-2023: An Opportunity for Intervention. [PDF]

Public Health Rep
Farrell CM, Pino EC.
europepmc   +1 more source

Typing of hepatitis C virus genomes by restriction fragment length polymorphism

, 1991
T. Nakao, Naoya Enomoto, Nobuo Takada, Akikazu Takada, T Date   +4 more
openalex   +1 more source